Your browser doesn't support javascript.
loading
SI-CLP inhibits the growth of mouse mammary adenocarcinoma by preventing recruitment of tumor-associated macrophages.
Yin, Shuiping; Wang, Nan; Riabov, Vladimir; Mossel, Dieuwertje M; Larionova, Irina; Schledzewski, Kai; Trofimova, Olga; Sevastyanova, Tatyana; Zajakina, Anna; Schmuttermaier, Christina; Gratchev, Alexei; Flatley, Andrew; Kremmer, Elisabeth; Zavyalova, Marina; Cherdyntseva, Nadezhda; Simon-Keller, Katja; Marx, Alexander; Klüter, Harald; Goerdt, Sergij; Kzhyshkowska, Julia.
Affiliation
  • Yin S; Medical Faculty Mannheim, Institute for Transfusion Medicine and Immunology, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Wang N; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Riabov V; Department of Dermatology, Medical Faculty Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Mossel DM; Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science andTechnology, Wuhan, China.
  • Larionova I; Medical Faculty Mannheim, Institute for Transfusion Medicine and Immunology, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Schledzewski K; Laboratory of Translational Cellular and Molecular Biomedicine, Tomsk State University, Tomsk, Russia.
  • Trofimova O; Medical Faculty Mannheim, Institute for Transfusion Medicine and Immunology, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Sevastyanova T; Laboratory of Translational Cellular and Molecular Biomedicine, Tomsk State University, Tomsk, Russia.
  • Zajakina A; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia.
  • Schmuttermaier C; Department of Dermatology, Medical Faculty Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Gratchev A; Latvian Biomedical Research and Study Centre, Riga, Latvia.
  • Flatley A; Medical Faculty Mannheim, Institute for Transfusion Medicine and Immunology, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Kremmer E; Latvian Biomedical Research and Study Centre, Riga, Latvia.
  • Zavyalova M; Medical Faculty Mannheim, Institute for Transfusion Medicine and Immunology, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Cherdyntseva N; Department of Dermatology, Medical Faculty Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Simon-Keller K; Laboratory for Tumor Stromal Cell Biology, Institute of Carcinogenesis, NN Blokhin Cancer Research Center, Russian Academy of Sciences, Moscow, Russia.
  • Marx A; Institute of Molecular Immunology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany.
  • Klüter H; Institute of Molecular Immunology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany.
  • Goerdt S; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia.
  • Kzhyshkowska J; Laboratory of Translational Cellular and Molecular Biomedicine, Tomsk State University, Tomsk, Russia.
Int J Cancer ; 146(5): 1396-1408, 2020 03 01.
Article in En | MEDLINE | ID: mdl-31525266
ABSTRACT
Chitinase-like proteins (CLP) are chitin-binding proteins that lack chitin hydrolyzing activity, but possess cytokine-like and growth factor-like properties, and play crucial role in intercellular crosstalk. Both human and mice express two members of CLP family YKL-40 and stabilin-1 interacting chitinase-like protein (SI-CLP). Despite numerous reports indicating the role of YKL-40 in the support of angiogenesis, tumor cell proliferation, invasion and metastasis, the role of its structurally related protein SI-CLP in cancer was not reported. Using gain-of-function approach, we demonstrate in the current study that the expression of recombinant SI-CLP in mouse TS/A mammary adenocarcinoma cells results in significant and persistent inhibition of in vivo tumor growth. Using quantitative immunohistochemistry, we show that on the cellular level this phenomenon is associated with reduced infiltration of tumor-associated macrophages (TAMs), CD4+ and FoxP3+ cells in SI-CLP expressing tumors. Gene expression analysis in TAM isolated from SI-CLP-expressing and control tumors demonstrated that SI-CLP does not affect macrophage phenotype. However, SI-CLP significantly inhibited migration of murine bone-marrow derived macrophages and human primary monocytes toward monocyte-recruiting chemokine CCL2 produced in the tumor microenvironment (TME). Mechanistically, SI-CLP did not affect CCL2/CCR2 interaction, but suppressed cytoskeletal rearrangements in response to CCL2. Altogether, our data indicate that SI-CLP functions as a tumor growth inhibitor in mouse breast cancer by altering cellular composition of TME and blocking cytokine-induced TAM recruitment. Taking into consideration weak to absent expression of SI-CLP in human breast cancer, it can be considered as a therapeutic protein to block TAM-mediated support of breast tumor growth.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Calcium-Binding Proteins / Carrier Proteins / Macrophages / Mammary Neoplasms, Experimental Type of study: Risk_factors_studies Limits: Animals / Female / Humans / Middle aged Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Calcium-Binding Proteins / Carrier Proteins / Macrophages / Mammary Neoplasms, Experimental Type of study: Risk_factors_studies Limits: Animals / Female / Humans / Middle aged Language: En Year: 2020 Type: Article